The optimal cutoff value for serum IBIL was 2.5 μg/L with a sensitivity of 27.6% and specificity of 94.25% suggesting that IBLB inhibits the mTOR pathway by altering the activity of the AMPK pathway leading to lung cancer metastasis. Here, MTOR is linked to lung carcinoma.